Ablation Strategies for Persistent Atrial Fibrillation Combined With Heart Failure
Clinical Study on the 2C3L Strategy Based on Marshall Venous Chemoablation for the Treatment of Persistent Atrial Fibrillation Combined With Heart Failure
Qianfoshan Hospital
130 participants
Jun 16, 2022
INTERVENTIONAL
Conditions
Summary
(1) To evaluate the efficacy and safety of "2C3L" strategy combined with VOM anhydrous ethanol chemical ablation for persistent atrial fibrillation complicated with heart failure; (2) To evaluate the effectiveness of high-efficiency ablation of atrial fibrillation complicated with heart failure.
Eligibility
Inclusion Criteria5
- age:18y-80y
- First ablation on non valvular atrial fibrillation
- Persistent atrial fibrillation with LVEF≤40%
- The patient has symptoms related to atrial fibrillation, including but not limited to palpitations, premonitory syncope, syncope, fatigue, and shortness of breath, and is evaluated for clinical cardiac function between NYHA II-IV levels
- No response to antiarrhythmic drugs, unacceptable side effects, or unwillingness to take antiarrhythmic drugs.
Exclusion Criteria10
- Paroxysmal atrial fibrillation
- Atrial fibrillation secondary to obvious reversible causes
- Echocardiography: Parasternal long axis section, left atrial diameter ≥ 60mm
- LVEF \>40%
- Receiving dual antithrombotic therapy
- Contraindications to the use of oral anticoagulants
- Contraindications to right or left cardiac catheterization
- pregnancy
- Life expectancy\<1 year (such as advanced malignant tumors, advanced kidney disease, etc.)
- Unable to discontinue antiarrhythmic drugs due to reasons other than atrial fibrillation
Interventions
Annular pulmonary vein ablation, mitral isthmus line ablation, tricuspid isthmus line ablation, apex line ablation，anhydrous alcohol ablation of VOM
Annular pulmonary vein ablation, mitral isthmus line ablation, tricuspid isthmus line ablation, apex line ablation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06438692